MedTrace Logo

Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

NCT00683319 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2013-09-20

No results posted yet for this study

Summary

RATIONALE: Gathering information about how young patients with ependymoma respond to standard combination chemotherapy and learning about the long-term effects of this treatment may help doctors plan better treatment.

PURPOSE: This phase III trial is observing young patients with ependymoma undergoing standard combination chemotherapy.

Conditions

Interventions

DRUG

carboplatin

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

methotrexate

DRUG

vincristine sulfate

PROCEDURE

adjuvant therapy

PROCEDURE

cognitive assessment

PROCEDURE

magnetic resonance imaging

PROCEDURE

magnetic resonance spectroscopic imaging

PROCEDURE

quality-of-life assessment

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Martin W. English, MD · Birmingham Children's Hospital

Eligibility

Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2034-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683319 on ClinicalTrials.gov